AtlasMedx, Inc is focused on discovering and developing innovative and transformational small molecule drugs to treat and conquer cancer.


AtlasMedx therapeutic strategy consists of a platform of breakthrough synthetically lethal anti-cancer medicines that simultaneously target compensatory DNA repair, cell division, and migration mechanisms to selectively kill cancer cells and overcome resistance to chemotherapy while protecting healthy cells.

AtlasMedx is advancing AMXI-5001, an orally bioavailable, small-molecule dual PARP (poly adenosine diphosphate [ADP] ribose polymerase and microtubule polymerization inhibitor.
(ClinicalTrials.gov website)

learn more